top of page
Search
The LOE cliff
Some of the most widely prescribed and profit‑generating biologic therapies are set to lose exclusivity over the next few years, yet only a fraction have a biosimilar competitor currently in development.
Jul 13
Biosimilars are Ascendant
Explore the evolving landscape of biosimilars in the US market, from legislative influences to industry challenges, with expert insights.
Dec 19, 2023
bottom of page